Monogenic (Mendelian): 100%, DM1 (DMPK CTG expansion) and DM2 (CNBP CCTG expansion); shows anticipation[1]
Inherited Cardiac Conditions reference
Definition: An autosomal dominant multisystem disorder caused by a nucleotide-repeat expansion (DMPK or CNBP), featuring myotonia, progressive myopathy and prominent cardiac conduction disease and arrhythmia.[1]
Monogenic (Mendelian): 100%, DM1 (DMPK CTG expansion) and DM2 (CNBP CCTG expansion); shows anticipation[1]
Inheritance: Autosomal dominant with anticipation, repeat length increases and disease severity worsens in successive generations.[2]
Familial proportion: Nearly 100% of cases are inherited from an affected parent; de novo repeat expansions are extremely rare. First-degree relatives (parent, sibling, child) have a 50% risk of inheriting the mutation. Offspring of affected mothers are at particular risk of the severe congenital form (DM1) due to maternal anticipation.[2]
DM1: DMPK gene (CTG repeat expansion); normal <37 repeats; pathogenic ≥50 repeats
DM2: CNBP gene (CCTG repeat expansion); typically milder cardiac involvement than DM1
Confirming the diagnosis: genetic testing, a CTG repeat expansion in DMPK confirms DM1; a CCTG expansion in CNBP (ZNF9) confirms DM2. DM1 carries the greater cardiac (conduction-disease) risk.[1]
Neuromuscular: Myotonia (delayed muscle relaxation), distal weakness, facial weakness
Cardiac (major cause of death):
Other: Cataracts, endocrinopathy, cognitive impairment
ECG: PR prolongation, AV block, QRS widening, atrial arrhythmias, annual minimum[3]
Holter: Annual 24-hour Holter to detect paroxysmal arrhythmias[2]
Echo: Assess LV function (cardiomyopathy is a late feature)
EP study: Consider if syncope or high-risk ECG features, HV interval ≥70ms predicts need for pacemaker[1]
Genetic testing: CTG/CCTG repeat sizing (diagnostic)
Cardiac monitoring:
Pacemaker:
ICD: Secondary prevention; primary prevention if high-risk features + cardiomyopathy
Note: Pacemaker does NOT eliminate SCD risk (ventricular arrhythmias still occur)
Cardiac disease accounts for ~30% deaths (sudden death, heart failure)
Respiratory failure also major cause of death
Based on ESC 2022 Ventricular Arrhythmia guidelines and myotonic dystrophy cardiac data[3][1].
Advanced / complicated = PR/QRS prolongation or other conduction disease, syncope, documented arrhythmia, or a device in situ.
Genotype-positive / phenotype-negative (G+/P−) = a confirmed pathogenic-variant carrier with no overt disease expression yet.
| Genotype+ / Phenotype− | Uncomplicated / Stable | Advanced / Complicated | |
|---|---|---|---|
| Frequency | Annual (monitor for conduction disease) | Annual | Every 6 months |
| Clinical review | Symptoms, syncope | Syncope, palpitations, symptoms | As above + device check |
| ECG | Annual (PR & QRS) | Annual 12-lead (PR & QRS trend) | Each visit |
| Holter / ambulatory | Periodic | Annual (AF, conduction, VT) | 6-monthly or symptom-directed |
| Echocardiography | Every 1–3 years | Every 1–3 years | Annual |
| EPS / device | If conduction disease emerges | Consider if PR/QRS prolongation or syncope | As indicated |
Disclaimer: This table is general guidance based on published guidelines and does not replace clinical judgement. The responsible clinician is accountable for determining the appropriate, individualised follow-up plan for each patient.
Last reviewed: June 2026